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Abstract
Objective
To develop a prediction model for term infants born large for gestational age (LGA) by cus-
tomised birthweight centiles.
Methods
International prospective cohort of nulliparous women with singleton pregnancy recruited to
the Screening for Pregnancy Endpoints (SCOPE) study. LGA was defined as birthweight
above the 90th customised centile, including adjustment for parity, ethnicity, maternal height
and weight, fetal gender and gestational age. Clinical risk factors, ultrasound parameters
and biomarkers at 14–16 or 19–21 weeks were combined into a prediction model for LGA
infants at term using stepwise logistic regression in a training dataset. Prediction perfor-
mance was assessed in a validation dataset using area under the Receiver Operating Char-
acteristics curve (AUC) and detection rate at fixed false positive rates.
Results
The prevalence of LGA at term was 8.8% (n = 491/5628). Clinical and ultrasound factors
selected in the prediction model for LGA infants were maternal birthweight, gestational
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weight gain between 14–16 and 19–21 weeks, and fetal abdominal circumference, head cir-
cumference and uterine artery Doppler resistance index at 19–21 weeks (AUC 0.67; 95%CI
0.63–0.71). Sensitivity of this model was 24% and 49% for a fixed false positive rate of 10%
and 25%, respectively. The addition of biomarkers resulted in selection of random glucose,
LDL-cholesterol, vascular endothelial growth factor receptor-1 (VEGFR1) and neutrophil
gelatinase-associated lipocalin (NGAL), but with minimal improvement in model perfor-
mance (AUC 0.69; 95%CI 0.65–0.73). Sensitivity of the full model was 26% and 50% for a
fixed false positive rate of 10% and 25%, respectively.
Conclusion
Prediction of LGA infants at term has limited diagnostic performance before 22 weeks but
may have a role in contingency screening in later pregnancy.
Introduction
Large for gestational age (LGA) is usually defined as birth weight above the 90th centile and is
associated with adverse perinatal outcomes [1]. Several reports, including observational studies
and a meta-analysis of two small randomised controlled trials, assessed induction of labour for
suspected large fetuses, and concluded that induction did not significantly reduce adverse out-
comes [2, 3]. However, a recent large randomised controlled trial (RCT) of induction of labour
versus expectant management in suspected LGA pregnancies demonstrated that induction of
labour at 37–39 weeks was associated with a 68% reduction in related adverse outcomes [4]. In
light of this evidence, new strategies are needed to improve antenatal identification of LGA
infants.
At present in most settings, screening for LGA is based on abdominal palpation and/or fun-
dal height measurement and in some cases referral for ultrasound, although this is not consis-
tent practice. The estimated sensitivity of these clinical methods is between 9.7% and 16.6%
[5–7]. Routine third trimester ultrasound in unselected populations has better performance in
detecting abnormal growth however is not universal practice [8]. Development of reliable
early pregnancy prediction models for LGA infants would offer the opportunity to undertake
trials of interventions that may prevent fetal overgrowth (primary prevention) or could inform
which women are more likely to benefit from a third trimester ultrasound and help direct
resources. The latter would allow appropriate management of labour and delivery in order to
reduce the likelihood of complications (secondary prevention).
Using data from the Screening for Pregnancy Endpoints (SCOPE) study, a prospective
international cohort of nulliparous pregnant women, our group previously reported that LGA
as defined by customised centiles, which adjusts for maternal ethnicity, height, early pregnancy
weight, parity, gestation at delivery and infant sex, was more strongly associated with adverse
perinatal outcomes compared to LGA defined by population centiles or birthweight above
4000g [9]. The aim of the present study was to assess the performance of early pregnancy fac-
tors for prediction of LGA at term defined by customised centiles.
Methods
SCOPE is an international prospective cohort study involving centres in Auckland, New Zea-
land; Adelaide, Australia; London, Manchester and Leeds, UK; and Cork, Ireland. Ethical
Early prediction of large for gestational age infants
PLOS ONE | https://doi.org/10.1371/journal.pone.0178484 June 1, 2017 2 / 12
Board. The SCOPE Consortium is keen to promote
collaboration among researchers and to see our
unique SCOPE database and pregnancy biobank
used in studies which meet our ethics and
consenting process. Therefore, we are a member
of the MotherChild Link Registry, http://www.
linkregistry.org/search.aspx.
Funding: The Australian SCOPE study was
supported by the Premier’s Science and Research
Fund, South Australian Government, and a NHMRC
project grant (GNT519225). The New Zealand
SCOPE study was funded by the New Enterprise
Research Fund, Foundation for Research Science
and Technology; Health Research Council [04/
198]; Evelyn Bond Fund, Auckland District Health
Board Charitable Trust. The Irish SCOPE study was
funded by the Health Research Board of Ireland
[CSA/2007/2]. The UK SCOPE study was funded by
National Health Service NEAT Grant [Neat Grant
FSD025], Biotechnology and Biological Sciences
Research council [GT084] and University of
Manchester Proof of Concept Funding (University
of Manchester); Guy’s and St. Thomas’ Charity
(King’s College London) and Tommy’s Charity
(King’s College London and University of
Manchester); and Cerebra UK (University of
Leeds). Biomarker measurement was funded by an
unrestricted research grant from Alere Inc, San
Diego, CA. MCV is supported by a Science Without
Borders Fellowship from CAPES (BEX: 9571/13-2).
LCK is supported by a Science Foundation Ireland
Program Grant for INFANT (12/RC/2272). DP and
LP are supported by Tommy’s Charity, UK. Open
access for this article was funded by King’s College
London (Open Scholarship Fund). The funders had
no role in study design, data collection and
analysis, decision to publish or preparation of the
manuscript.
Competing interests: LCK has a consultancy
relationship with Alere. PNB and LCK are minority
shareholders in Metabolomic Diagnostics, an SME
who have licensed IP pertaining to the prediction of
preeclampsia from UCC. In addition, PNB and LCK
declare a US patent PCT/EP2010/070446 and LP
declares patent PCT number GB01/04892. The
Alere funding was used for sample retrieval and
shipping, database sharing, and the time university
employed researchers spent on the project. Alere
developed the immunoassays and performed the
biomarker measurements, but was blinded to
clinical data and endpoints. In addition, Alere and
other funders had no role in study design, data
collection and analysis, and decision to publish or
the data included in this publication. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials (as detailed online in the
approval was obtained from local ethics committees (New Zealand AKX/02/00/364, Australia
REC 1712/5/2008, London, Leeds and Manchester 06/MRE01/98 and Cork ECM5 (10) 05/02/
08) and all women provided written informed consent prior to entering the study.
SCOPE recruited healthy nulliparous women with singleton pregnancies at 14–16 weeks
between November 2004 and February 2011 [10]. Women were excluded if they were at high
risk of preeclampsia, small for gestational age (SGA) or preterm birth because of underlying
medical conditions, had at least three previous miscarriages or terminations of pregnancy,
with major fetal anomaly or abnormal karyotype prior to recruitment, or those who received
interventions that may modify pregnancy outcome. Extensive information was collected on
socio-demographic and clinical characteristics, and blood samples were also obtained. The
data collected and sample storage and analysis are described in detail elsewhere [11]. At 19–21
weeks, women returned for clinical assessment and a fetal ultrasound scan for biometry and
uterine and umbilical artery Doppler waveform analysis. Women were followed up within 72
hours of delivery and data on pregnancy and neonatal outcome were collected [10].
The date of last menstrual period (LMP) was used to determine the estimated due date
(EDD) which was then confirmed by ultrasound. The EDD was only corrected if (i) a scan per-
formed before 16 weeks identified a difference of seven days or more or (ii) the 20 weeks scan
identified a difference of 10 days or more between the scan EDD and the LMP EDD. If the
EDD based on LMP was uncertain then the EDD was based on the scan. For the majority of
participants (96%), an ultrasound before 16 weeks was available to confirm, correct, or assign
the EDD.
Outcomes of interest
A LGA infant born at term, was defined as an infant born at or beyond 37 weeks with a birth-
weight above the 90th customised centile. Fetal growth above the 95th customised centile was
also explored. Customised centiles were calculated correcting for gestational age, maternal eth-
nicity, height and weight in early pregnancy, parity and infant sex [12].
Exposures
The selection of clinical factors for prediction of LGA at term was based on a-priori hypothesis
of biological plausibility and/or known association with LGA. Those included were maternal
birthweight, maternal preterm birth, family history of diabetes, maternal anthropometry at
14–16 weeks (body mass index (BMI), height, weight, waist, hip, waist-hip ratio, waist-height
ratio, arm circumference and head circumference), pulse and systolic blood pressure at 14–16
weeks. At 19–21 weeks, gestational weight gain between 14–16 and 19–21 weeks (measured in
kg/week), smoking status and history of never exercising were selected. Ultrasound parameters
measured at the 19–21 weeks scan included head circumference (HC), abdominal circumfer-
ence (AC), femur length (FL), uterine artery Doppler resistance index (RI), and umbilical
artery Doppler RI.
A group of candidate biomarkers, comprised of 7 biomarkers associated with obesity and /
or with a role in glucose or lipid metabolism, were measured in samples from 14–16 weeks.
Random whole blood glucose concentrations at 14–16 weeks and 19–21 weeks were also
included [10]. An additional 46 biomarkers measured in samples from 14–16 weeks and previ-
ously reported in SCOPE were also explored [11]. These biomarkers were related to placenta-
tion, inflammation and angiogenesis. Of the full list of 55 biomarkers available for analysis, 10
had>40% of measurements on or below the limit of detection and therefore were excluded
from further analysis. The methodology for the measurements of all biomarkers is provided in
S1 Appendix and summarised in S1 Table.
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Statistical analysis
All participants with outcome data were included in the analysis. Missing data for clinical and
ultrasound predictors were minimal (2%), except for maternal birthweight (5.2%), gesta-
tional weight gain between 14–16 and 19–21 weeks (3.0%), smoking status at 19–21 weeks
(2.6%), exercise at 19–21 weeks (3.0%), average uterine artery Doppler (6.1%), and random
glucose at 19–21 weeks (3.5%). Missing data were imputed for analyses using expected maxi-
mization, or for variables unrelated to other data points that had<1% missing data, single
imputation was performed using the median (continuous variables) or mode (binary/categori-
cal variables) as previously described [9]. We chose this method of imputation to allow calcula-
tion of post estimation parameters in model selection. To confirm our findings, we performed
a sensitivity analysis using multiple imputation by chained equations and compared the coeffi-
cients of final prediction models between the two methods of imputation.
The dataset was randomly divided into training and validation cohorts, stratified for geo-
graphical area (Australasian centres and European centres) in a ratio of 2:1. Development of
prediction models was performed using the training dataset and performance assessed in the
validation dataset. Continuous factors were assessed for linearity and variation with gestational
age. In total, 10 biomarkers required multiple of median (MoM) transformation (brain natri-
uretic peptide (BNP), fas cell surface death receptor (FAS), nephrin, plasminogen activator
inhibitor 2 (PAI-2), pregnancy associated plasma protein A (PAPP-A), placental growth factor
(PlGF), total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides). All biomarkers
were log transformed for analyses. Ultrasound biometry parameters (HC, AC and FL) were
transformed into z-scores and uterine artery and umbilical artery Doppler RI was transformed
into MoM for gestational age. Univariate analyses were performed using t-test, Mann-Whitney
test or Χ2 test, as appropriate. Factors for model selection were chosen based on a-priori
hypotheses except for the additional biomarkers where p<0.01 was used for inclusion.
Model selection was performed using stepwise selection based on Bayesian Information
Criterion (BIC) as the stopping rule. The prediction model was developed in stages, which
included different combination of groups of predictors based on applicability in clinical prac-
tice. Factors included in each model were: model 1—clinical factors at 14–16 weeks; model 2—
clinical factors and candidate biomarkers at 14–16 weeks; model 3—clinical factors and ultra-
sound at 14–16 and 19–21 weeks; model 4—clinical factors, ultrasound and candidate bio-
markers at 14–16 and 19–21 weeks; and model 5—full model including additional list of
biomarkers. Performance of prediction models was assessed based on the area under the
Receiver Operating Characteristic curve (AUC). The detection rate at a fixed false positive rate
(FPR) of 10 and 25% was also estimated. LGA at term (birthweight above the 90th centiles at or
beyond 37 weeks) was the outcome used for primary analysis (univariate analysis, model
development and test performance). A sensitivity analysis of model performance using birth-
weight at term above the 95th centile as the outcome was also performed. Imputation using
expected maximization was performed using “mix” package in R, version 2.9.1, (R Foundation,
Vienna, Austria) and SPSS, version 24.0 (IBM Corp, Armonk, US). Statistical analysis and
multiple imputation by chained equations were performed in STATA software, version 13.0
(StataCorp LP, College Station, Texas). This study has been reported in line with STROBE rec-
ommendations [13].
Results
Of the 5690 women recruited to SCOPE, 62 (1.1%) were excluded from analysis due to proto-
col violation or loss of follow up (Fig 1). The study population comprised 5628 women and the
prevalence of LGA by customised centiles at term was 8.8% (n = 491).
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The prevalence of LGA at term by customised centiles in the training (n = 3752) and
validation (n = 1876) dataset was similar (8.8%, n = 331 and 8.5%, n = 160, respectively).
Demographic characteristics and pregnancy outcomes of women in the training dataset are
described in Table 1. Women delivering an LGA infant were more likely to develop gestational
diabetes, deliver by caesarean section and have postpartum haemorrhage.
Univariate comparison of pregnancy factors between LGA and non-LGA infants in the
training dataset is described in S2 Table. Mothers of LGA infants had a higher birthweight,
larger maternal head circumference, higher pulse and lower blood pressure at 14–16 weeks. At
19–21 weeks they were less likely to smoke and had a higher gestational weight gain between
14–16 and 19–21 weeks. Fetal HC, AC and FL z-scores at 19–21 weeks ultrasound were greater
in LGA infants, and a lower uterine artery and umbilical artery RI was observed. Women who
delivered LGA infants had a higher random glucose, total cholesterol and LDL-cholesterol
concentration at 14–16 weeks, and higher random glucose concentration at 19–21 weeks.
From the additional biomarkers, neutrophil gelatinase-associated lipocalin (NGAL), PAPP-A,
and vascular endothelial growth factor receptor-1 (VEGFR1) were associated with LGA
(p<0.01) and were included in the model selection process.
The prediction models developed are described in Table 2. Maternal birthweight was the
only clinical factor at 14–16 weeks that was selected as a predictor in model 1. The addition
of candidate biomarkers selected maternal birthweight, random glucose and LDL-cholesterol
at 14–16 weeks (model 2). The model with clinical factors at 14–16 and 19–21 weeks and ul-
trasound included maternal birthweight, gestational weight gain between 14–16 and 19–21
weeks, fetal AC and HC z-scores on ultrasound, and uterine artery Doppler RI (model 3). The
addition of candidate biomarkers measured to model 3 included random glucose at 14–16
weeks and 19–21 weeks (model 4). A complete model with clinical factors at 14–16 and 19–21
weeks, candidate and additional biomarkers and ultrasound included all the factors identified
in model 4, VEGFR1 and NGAL (model 5).
Fig 1. Study population.
https://doi.org/10.1371/journal.pone.0178484.g001
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The performance of different predictive models in training and validation datasets is
described in Table 3 and the receiver operator characteristics curve in the validation dataset
plotted in Fig 2. Model 1, which selected only one clinical factor at 14–16 weeks had poor per-
formance. This was improved with the addition of clinical and ultrasound parameters at 19–21
weeks (Model 3; AUC 0.67, 0.63 to 0.71; p = 0.001 for comparison with Model 1; validation
dataset). The full model including clinical factors, ultrasound and biomarkers produced an
AUC of 0.69 (0.65 to 0.73; validation dataset) (Model 5), which was not statistically different
from Model 3 (p = 0.21). For a fixed FPR of 10% and 25%, the detection rates (DR) in the vali-
dation dataset were 24% and 49% for model 3 and 26% and 50% for Model 5, respectively. A
sensitivity analysis assessing model performance using birthweight above the 95th centiles as
the outcome produced very similar results (S3 Table). Similar coefficients for the five predic-
tion models were observed in the sensitivity analysis using multiple imputation by chained
equations (S4 Table).
Table 1. Demographic characteristics and pregnancy outcomes by LGA status.
Non-LGA at term LGA at term
(N = 3421; 91.2%) (N = 331; 8.8%)
Mean (SD) or n (%) Mean (SD) or n (%) p-value
Age (years) 28.5 (5.5) 28.9 (5.5) 0.31
Ethnicity
European 3091 (90.4) 289 (87.3)
Asian 100 (2.9) 10 (3.0) 0.25
Indian 80 (2.3) 14 (4.2)
Maori / Pacific Islander 64 (1.9) 8 (2.4)
Other 86 (2.5) 10 (3.0)
Married/cohabiting 3092 (90.4) 306 (92.4) 0.22
Tertiary education 2840 (83.0) 279 (84.3) 0.56
Family history of DM 453 (13.2) 54 (16.3) 0.12
Gestational diabetes * † 76 (2.2) 14 (4.2) 0.02
Induction of labor † 1102 (32.8) 103 (32.2) 0.82
Mode of delivery †
Spontaneous vaginal 1596 (46.9) 96 (29.0) <0.001
Assisted vaginal 910 (26.7) 83 (25.1) 0.52
Elective section 287 (8.4) 51 (15.4) <0.001
Emergency section 612 (18.0) 101 (30.5) <0.001
Postpartum hemorrhage † 132 (4.6) 26 (9.4) 0.001
GA at delivery (wks) 39.5 (2.7) 39.8 (1.2) 0.11
Birthweight, grams † 3323 (552) 4198 (359) <0.001
Macrosomia (>4500g) † 223 (6.5) 228 (68.9) <0.001
Apgar<7 at 5 minutes † 49 (1.5) 1 (0.3) 0.09
NICU admission † 387 (11.3) 35 (10.6) 0.67
Severe neonatal morbidity † 102 (3.0) 13 (3.9) 0.35
Abbreviations: BP—blood pressure, DM—diabetes mellitus, GA—gestational age, LGA—large for gestational age, NICU—neonatal intensive care unit
* Women were referred for oral glucose tolerance test according to local policies. 1,300 (35%) women did not have any serum screening and this was a low
risk group that had lower prevalence of cesarean section and similar prevalence of postpartum hemorrhage and NICU admission compared to women
tested negative.
† Missing data for gestational diabetes (n = 14), induction of labor (n = 72), mode of delivery (n = 16), postpartum hemorrhage (n = 619), birthweight
(n = 15), macrosomia (n = 15), Apgar at 5 minutes (n = 64), NICU admission (n = 14) and severe neonatal morbidity (n = 14).
https://doi.org/10.1371/journal.pone.0178484.t001
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Table 2. Description of prediction models for LGA at term in training dataset.
Predictors Model 1 * Model 2 * Model 3 * Model 4 * Model 5 *
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
(n = 3,752) (n = 3,752) (n = 3,752) (n = 3,752) (n = 3,752)
Clinical factors at 14–16 weeks
Maternal birthweight (per 500g) 1.23 (1.11–1.37) 1.25 (1.13–1.39) 1.18 (1.06–1.31) 1.19 (1.07–1.33) 1.19 (1.06–1.32)
Candidate biomarkers at 14–16 weeks
Random glucose (per 0.2 log) 1.28 (1.12–1.45) 1.23 (1.08–1.41) 1.27 (1.11–1.45)
LDL- cholesterol (per 1 log of MoM) 1.85 (1.22–2.80)
Clinical factors and ultrasound at 19–21 weeks
Gestational weight gain (per 500g/week) 1.31 (1.14–1.50) 1.32 (1.14–1.51) 1.32 (1.14–1.53)
AC Z-score at ultrasound 1.52 (1.34–1.72) 1.51 (1.34–1.71) 1.52 (1.34–1.73)
HC Z-score at ultrasound 1.38 (1.21–1.57) 1.37 (1.21–1.57) 1.40 (1.22–1.59)
Uterine artery RI (per 0.2 MoM) 0.70 (0.61–0.81) 0.69 (0.60–0.79) 0.71 (0.62–0.82)
Candidate biomarkers at 19–21 weeks
Random glucose (per 0.2 log) 1.22 (1.07–1.39) 1.22 (1.07–0.39)
Additional biomarkers at 14–16 weeks
VEGFR1 (log) 1.67 (1.40–2.00)
NGAL (log) 0.62 (0.48–0.81)
Abbreviation: AC—abdominal circumference, HC—head circumference, MoM—multiple of median, NGAL—neutrophil gelatinase-associated lipocalin, RI—
resistance index, VEGFR1—vascular endothelial growth factor receptor type 1.
* Model 1—clinical factors at 14–16 weeks; Model 2—clinical factors and candidate biomarkers at 14–16 weeks; Model 3—clinical factors and ultrasound at
14–16 and 19–21 weeks; Model 4—clinical factors, ultrasound and candidate biomarkers at 14–16 and 19–21 weeks; Model 5—full model including
additional list of biomarkers.
https://doi.org/10.1371/journal.pone.0178484.t002
Table 3. Detection rate and area under the receiver operating characteristic of the prediction models for LGA at term.
Training dataset Validation dataset
Models * 10%
FPR
25%
FPR
AUC (95%CI) 10%
FPR
25%
FPR
AUC (95%CI)
1 MBW 14% 35% 0.57 (0.54–
0.60)
16% 38% 0.59 (0.54–
0.64)
2 MBW, gluc, and LDL (14-16w) 18% 38% 0.60 (0.57–
0.63)
11% 30% 0.56 (0.52–
0.61)
3 MBW, GWG, AC, HC, and UtRI (19-21w) 30% 55% 0.70 (0.67–
0.73)
24% 49% 0.67 (0.63–
0.71)
4 MBW, gluc (14-16w), GWG, AC, HC, UtRI, and gluc (19-21w) 33% 56% 0.72 (0.69–
0.75)
26% 48% 0.66 (0.62–
0.71)
5 MBW, gluc (14-16w), GWG, AC, HC UtRI, and gluc (19-21w), VEGFR1 and
NGAL (14-16w)
35% 60% 0.74 (0.71–
0.77)
26% 50% 0.69 (0.65–
0.73)
Abbreviations: AC—fetal abdominal circumference, AUC–area under the receiver operating characteristic, gluc—glucose, GWG–gestational weight gain
between 14–16 and 19–21 weeks, FPR–false positive rate, HC—fetal head circumference, LDL—LDL-cholesterol, MBW—maternal birthweight, NGAL—
neutrophil gelatinase-associated lipocalin, UtRI—uterine artery resistance index, VEGFR1—vascular endothelial growth factor receptor type 1, w—weeks.
* Model 1—clinical factors at 14–16 weeks; Model 2—clinical factors and candidate biomarkers at 14–16 weeks; Model 3—clinical factors and ultrasound at
14–16 and 19–21 weeks; Model 4—clinical factors, ultrasound and candidate biomarkers at 14–16 and 19–21 weeks; Model 5—full model including
additional list of biomarkers.
https://doi.org/10.1371/journal.pone.0178484.t003
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Discussion
We developed a prediction model for LGA at term defined using customised birthweight cen-
tiles. Maternal birthweight, gestational weight gain between 14–16 to 19–21 weeks, fetal AC
and HC z-score and uterine artery RI at the 19–21 weeks ultrasound contributed indepen-
dently to the prediction of LGA. Random glucose, VEGFR1 and NGAL at 14–16 weeks, and
random glucose at 19–21 weeks were also independent predictors. The performance of the full
prediction model was modest with an AUC of 0.69 (0.65 to 0.73) and a detection rate of 26%
and 50% for a fixed FPR of 10% and 25%, respectively.
At present, primary prevention of fetal overgrowth leading to LGA is limited by poor pre-
diction and by the lack of effective antenatal interventions in non-GDM pregnancies [14, 15].
However, secondary prevention to avoid complications of labour and delivery has now been
shown to be achievable in a well-designed randomised controlled trial [4]. In this large multi-
centre trial, Boulvain et al reported that induction of labour at 37+0 to 38+6 weeks in pregnan-
cies with suspected LGA infants (estimated fetal weight on ultrasound above the 95th centile
between 36–38 weeks) reduced the risk of shoulder dystocia and associated neonatal morbidity
(RR 0.32; 95%CI 0.15–0.71) without increasing caesarean section rates (RR 0.89; 95%CI 0.72–
1.09). Women were referred for ultrasound based on increased fundal height or fetal weight
estimated with the Leopold manoeuvres, although the sensitivity of the screening strategy was
not reported.
Studies reporting routine clinical detection of birthweight above the 90th centile for gesta-
tional age have described sensitivity between 9.7% and 16.6% [5–7]. These methods include
abdominal palpation with or without ultrasound. Using these methods the majority of infants
who would potentially benefit from induction of labour are not identified. The clinical applica-
bility of the prediction model reported in the present study is limited by its modest perfor-
mance. Nonetheless, it has potential future value in risk stratification, as the sensitivity of 25%
FPR (49%) is higher than current clinical practice. Contingency screening by mid pregnancy
Fig 2. Receiver operating characteristics curve for LGA prediction models in the validation dataset.
Model 1—clinical factors at 14–16 weeks; Model 2—clinical factors and candidate biomarkers at 14–16
weeks; Model 3—clinical factors and ultrasound at 14–16 and 19–21 weeks; Model 4—clinical factors,
ultrasound and candidate biomarkers at 14–16 and 19–21 weeks; Model 5—full model including additional list
of biomarkers.
https://doi.org/10.1371/journal.pone.0178484.g002
Early prediction of large for gestational age infants
PLOS ONE | https://doi.org/10.1371/journal.pone.0178484 June 1, 2017 8 / 12
risk stratification, and referral of high risk women for late third trimester scan could reduce
the FPR and direct resources to women at higher risk of LGA. Although one in every four
women would require a third trimester scan, the addition of clinical factors in late pregnancy
such as maternal weight gain could further improve the model and reduce the number of
scans. Registry studies reported that late 3rd trimester ultrasound has a sensitivity and specific-
ity of 72–73% and 87–90% for LGA, respectively [16, 17]. However, this is not universal prac-
tice due to increased antenatal health care costs and utilization of ultrasound services. Further
studies are required to assess effectiveness and health economic benefits of contingency
screening and universal third trimester ultrasound to clarify which is the most cost-effective
approach in the detection of LGA.
In contrast to previous reports predicting LGA by population centiles, in our cohort mater-
nal anthropometric measures were not associated with LGA by customised centiles [17, 18].
This may relate to the adjustment for maternal weight and height in the estimation of custom-
ised centiles. Our prediction model was substantially driven by the ultrasound parameters at
19–21 weeks, suggesting that fetal overgrowth may be established as early as 19–21 weeks in
some women. Amongst ultrasound parameters, AC z-score had the stronger association with
LGA and this agrees with previous reports in which AC and estimated fetal weight at the last
available scan were the best predictors of term and preterm LGA [19, 20]. Furthermore in con-
trast to our cohort of nulliparous women, these previous models were developed from unse-
lected populations which included multiparous women. A previous LGA infant is a recognised
risk factor for a subsequent LGA infant. However, mode of delivery in previous pregnancy will
provide reassurance for management of subsequent pregnancy which limits clinical relevance
of prediction in multiparous compared with nulliparous women. Lack of a past obstetric his-
tory in nulliparous women also increases the potential value of a predictive tool. The contribu-
tion of maternal anthropometrics and previous LGA are likely related to the higher AUC
(0.79; 95% CI 0.79–0.79) at 19–24 weeks observed by Frick et al [17]. They have also shown
that prediction is improved with ultrasound in later gestations. At 30–34 weeks, their predic-
tion model using maternal characteristics and fetal biometry achieved an AUC of 0.85 (0.85–
0.86), however only one third of their population had ultrasound at that gestation. It is likely
that performance would be considerably lower if the two thirds of women without available
ultrasound were accounted for. Clinical translation of their finding is limited as universal third
trimester screen is not available at present in the UK and the majority of countries worldwide.
Mechanistically, elevated maternal glucose concentrations provide the traditional explana-
tion for accelerated fetal growth which has been emphasised in a recent study using mendelian
randomization, suggesting maternal BMI and blood glucose are likely to be causally associated
with higher offspring birthweight [21]. In the absence of overt hyperglycaemia, maternal insu-
lin and triglycerides may signal increased placental transport of fatty acids leading ultimately
to macrosomia [22–24]. Although an independent association between glucose and LDL-cho-
lesterol with LGA was shown in our study, the contribution to the predictive performance was
minimal (Table 3). The lack of association with triglycerides may reflect the time of measure-
ment at 14–16 weeks, which may have little relevance to later fetal growth, [25] or, alterna-
tively, previously observed association could be explained by unmeasured confounders, as this
association was also not apparent using mendelian randomisation [21]. VEGFR1 is the recep-
tor for vascular endothelial growth factor (VEGF) and provided a mild increase in the AUC.
The use of biomarkers did not improve overall performance of the prediction of LGA in early
pregnancy.
SCOPE was not developed with the primary aim of early prediction of LGA but this rich
dataset provides an opportunity for testing further hypotheses using this well characterised
cohort with highly complete data. This cohort which is enriched with early pregnancy factors
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provides the opportunity to explore their contribution to the prediction of LGA. Another
strength of this study is internal validation in a separate dataset of SCOPE participants, which
differs from previous studies [17, 18]. A limitation is the wide variation in the screening for
gestational diabetes mellitus (GDM), which was performed according to local policy in each
centre. However, the prevalence of LGA associated with known GDM was small (5%) and our
results were consistent in a sensitivity analysis excluding all cases of GDM. Other limitations
include the gestation of biomarker measurement (14–16 weeks), which is not the time of a rou-
tine antenatal visit in many countries.
Conclusion
In this study, we have developed a prediction model for LGA by customised centiles at term.
Overall, the performance of prediction models for LGA up to 22 weeks is limited and the addi-
tion of biomarkers does not improve performance. Other strategies such as contingency
screening, with risk stratification at 20 weeks and tailored ultrasound assessment in the late
third trimester, or universal third trimester ultrasound screening are likely to improve antena-
tal detection of LGA infants. Further studies need to explore benefits and health economic
costs of these different screening strategies.
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